Oxford Bioscience Partners News
Most Popular Oxford Bioscience Partners Story
Pfizer strikes deal for UK's PowderMed
Pfizer has struck a deal to buy the UK's PowderMed, a company that has been developing a new generation of DNA-based vaccines. No terms were disclosed. PowderMed has attracted attention for its needle-free technology for delivering DNA-based vaccines. PowderMed researchers blast the skin of patients with microscopic gold particles coated with the vaccine, an approach that allows for the …
Read more...Latest Headlines
- January 12, 2011
- March 10, 2008
- October 25, 2007
- January 24, 2007
- January 18, 2007
- November 27, 2006
- November 8, 2006
- October 24, 2006
- October 8, 2006
- December 19, 2005
- December 18, 2005
- August 29, 2005
- July 27, 2005
- July 14, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
